Amgen to Present at Lazard Capital Healthcare Conference Read more about Amgen to Present at Lazard Capital Healthcare Conference
Amgen to Present at 18th Annual Credit Suisse Healthcare Conference Read more about Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer Read more about Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Call for Applications: The Amgen Award for Science Teaching Excellence Read more about Call for Applications: The Amgen Award for Science Teaching Excellence
Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints Read more about Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49 Read more about Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49
Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA) Read more about Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting Read more about Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting
Amgen Announces Webcast of 2009 Third Quarter Financial Results Read more about Amgen Announces Webcast of 2009 Third Quarter Financial Results
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer Read more about Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
